These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 27213520)

  • 1. Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics.
    Abedini A; Plesner A; Cao P; Ridgway Z; Zhang J; Tu LH; Middleton CT; Chao B; Sartori DJ; Meng F; Wang H; Wong AG; Zanni MT; Verchere CB; Raleigh DP; Schmidt AM
    Elife; 2016 May; 5():. PubMed ID: 27213520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology.
    Jaikaran ET; Clark A
    Biochim Biophys Acta; 2001 Nov; 1537(3):179-203. PubMed ID: 11731221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus.
    Jeong HR; An SS
    Clin Interv Aging; 2015; 10():1873-9. PubMed ID: 26604727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice.
    Lin CY; Gurlo T; Kayed R; Butler AE; Haataja L; Glabe CG; Butler PC
    Diabetes; 2007 May; 56(5):1324-32. PubMed ID: 17353506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAGE binds preamyloid IAPP intermediates and mediates pancreatic β cell proteotoxicity.
    Abedini A; Cao P; Plesner A; Zhang J; He M; Derk J; Patil SA; Rosario R; Lonier J; Song F; Koh H; Li H; Raleigh DP; Schmidt AM
    J Clin Invest; 2018 Feb; 128(2):682-698. PubMed ID: 29337308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin improves glucose control and β-cell function in human IAPP transgenic mice by attenuating islet inflammation and reducing IAPP oligomers.
    Zhang Y; Yu XL; Zhu J; Liu SY; Liu XM; Dong QX; Chai JQ; Liu RT
    Int Immunopharmacol; 2018 Jan; 54():145-152. PubMed ID: 29145032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.
    Brender JR; Salamekh S; Ramamoorthy A
    Acc Chem Res; 2012 Mar; 45(3):454-62. PubMed ID: 21942864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The β-cell assassin: IAPP cytotoxicity.
    Raleigh D; Zhang X; Hastoy B; Clark A
    J Mol Endocrinol; 2017 Oct; 59(3):R121-R140. PubMed ID: 28811318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization of the hetero-assembly of β-amyloid peptide with islet amyloid polypeptide.
    Yan LM; Velkova A; Kapurniotu A
    Curr Pharm Des; 2014; 20(8):1182-91. PubMed ID: 23713771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes.
    Matveyenko AV; Butler PC
    ILAR J; 2006; 47(3):225-33. PubMed ID: 16804197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of islet amyloidosis toxicity in type 2 diabetes.
    Abedini A; Schmidt AM
    FEBS Lett; 2013 Apr; 587(8):1119-27. PubMed ID: 23337872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative molecular dynamics study of human islet amyloid polypeptide (IAPP) and rat IAPP oligomers.
    Liang G; Zhao J; Yu X; Zheng J
    Biochemistry; 2013 Feb; 52(6):1089-100. PubMed ID: 23331123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity.
    Paulsson JF; Benoit-Biancamano MO; Schäffer L; Dahl K
    Amyloid; 2011 Dec; 18(4):222-8. PubMed ID: 22047620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the Environmental Factors Affecting the Structural and Cytotoxic Properties of IAPP Peptides.
    Tomasello MF; Sinopoli A; Pappalardo G
    J Diabetes Res; 2015; 2015():918573. PubMed ID: 26582441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology.
    Akter R; Cao P; Noor H; Ridgway Z; Tu LH; Wang H; Wong AG; Zhang X; Abedini A; Schmidt AM; Raleigh DP
    J Diabetes Res; 2016; 2016():2798269. PubMed ID: 26649319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway.
    Gurlo T; Ryazantsev S; Huang CJ; Yeh MW; Reber HA; Hines OJ; O'Brien TD; Glabe CG; Butler PC
    Am J Pathol; 2010 Feb; 176(2):861-9. PubMed ID: 20042670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Baboon IAPP Provides Insight into Amyloidogenicity and Cytotoxicity of Human IAPP.
    Ridgway Z; Lee KH; Zhyvoloup A; Wong A; Eldrid C; Hannaberry E; Thalassinos K; Abedini A; Raleigh DP
    Biophys J; 2020 Mar; 118(5):1142-1151. PubMed ID: 32105649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Islet amyloid polypeptide exerts a novel autocrine action in β-cell signaling and proliferation.
    Visa M; Alcarraz-Vizán G; Montane J; Cadavez L; Castaño C; Villanueva-Peñacarrillo ML; Servitja JM; Novials A
    FASEB J; 2015 Jul; 29(7):2970-9. PubMed ID: 25808537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease.
    Horvath I; Wittung-Stafshede P
    Proc Natl Acad Sci U S A; 2016 Nov; 113(44):12473-12477. PubMed ID: 27791129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophages and pancreatic islet amyloidosis.
    de Koning EJ; van den Brand JJ; Mott VL; Chargé SB; Hansen BC; Bodkin NL; Morris JF; Clark A
    Amyloid; 1998 Dec; 5(4):247-54. PubMed ID: 10036582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.